Owens & Minor (NYSE:OMI) Updates FY25 Earnings Guidance

Owens & Minor (NYSE:OMI) issued an update on its FY25 earnings guidance on Friday morning. The company provided earnings per share guidance of $1.60-1.85 for the period, compared to the consensus earnings per share estimate of $1.79. The company issued revenue guidance of $10.85-11.15, compared to the consensus revenue estimate of $10.97 billion. Owens & Minor also updated its FY 2025 guidance to 1.600-1.850 EPS.

Owens & Minor Stock Up 38.7 %

Shares of OMI stock opened at $9.56 on Friday. Owens & Minor has a 12 month low of $6.07 and a 12 month high of $28.35. The firm has a market cap of $736.78 million, a PE ratio of -14.70, a price-to-earnings-growth ratio of 0.20 and a beta of 0.48. The stock has a 50 day moving average of $11.51 and a 200-day moving average of $13.24. The company has a quick ratio of 0.45, a current ratio of 1.09 and a debt-to-equity ratio of 2.11.

Owens & Minor (NYSE:OMI) last released its quarterly earnings data on Friday, February 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.02. The business had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.68 billion. Owens & Minor had a positive return on equity of 14.60% and a negative net margin of 0.46%. Owens & Minor’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.69 earnings per share. On average, equities analysts predict that Owens & Minor will post 1.51 EPS for the current year.

Owens & Minor announced that its Board of Directors has authorized a share repurchase plan on Friday, February 28th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 13.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on OMI. UBS Group lowered their price target on Owens & Minor from $25.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Barclays lowered their price target on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 5th. Citigroup lowered their price target on Owens & Minor from $21.00 to $18.50 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Finally, Robert W. Baird decreased their target price on Owens & Minor from $14.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Owens & Minor presently has an average rating of “Hold” and an average price target of $14.92.

About Owens & Minor

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.